However, treatment with SSRI has been associated with increased IL-2 levels and reduced symptoms in pediatric depression and anxiety in some studies (Henje-Blom et al., 2012; Lee et al., 2020; Pallavi et al., 2015; Pérez-Sánchez et al., 2018). This evidence concerns the gene IL2 and depressive symptom measurement.